Compare Etsy Inc (ETSY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Gilead Sciences, Inc. — how do they compare? Etsy Inc trades at $79.71 (market cap $7.29B), while Gilead Sciences, Inc. trades at $135.77 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 23.1× Etsy Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | GILD | |
|---|---|---|
Market Cap | $7.29B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.47 | $155.80 |
52-Week Low | $44.05 | $110.56 |
Enterprise Value | $9.25B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $80.40, down 6.02% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $0.98 beating expectations of $0.747, while announcing a 12% workforce reduction and $2 billion share repurchase program. Revenue trends show modest growth from $2.6B in 2022 to $2.9B in 2025, though net income margins have compressed from 11.19% in 2023 to 5.65% in 2025.
The outlook remains mixed with analyst consensus at Buy (46.7%) versus Hold (46.7%) and an $85.71 price target offering 6.6% upside. Key risks include high debt levels ($2.29B long-term debt), competitive pressures, and execution of restructuring. Positive catalysts include AI integration progress and operational efficiency improvements driving GMS growth acceleration to 7.5% year-over-year.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
